Hyperliquid CEO Jeff Yan Says Perpetual Futures Markets Can Democratize Access to Pre-IPO Companies. Here's Why He's Right.

Hyperliquid offers perpetual futures that provide synthetic exposure to private companies before IPOs, but holders receive no shares, voting rights, or claim on earnings. As of Oct. 15, its Anthropic perp implied a valuation of about $2 trillion—more than double the company’s most recent funding-round valuation—while Anthropic’s IPO filings were not yet public. The article advises investors to avoid these contracts because of valuation risk and limited access to financial information.

Analysis

The investable issue is not simply access to private-company upside; it is the basis and market structure embedded in these contracts. A perp can trade well above the last observable private round or eventual IPO reference, while holders have no equity, voting, or earnings claim. Around an IPO, that creates a potential convergence trade—but also funding, liquidation, oracle and liquidity risks that can make an apparently obvious short dangerous. A high implied valuation is not itself proof of mispricing when the reference company’s disclosures are incomplete.

Near term, the reported SpaceX post-launch premium and subsequent retreat illustrate how quickly sentiment can reprice once an IPO price becomes an anchor. That history is a caution, not evidence that SPCX or any current contract must repeat the move. Over 1–3 months, Anthropic’s public filings and IPO terms are the key catalysts: audited results, growth quality, cash burn and share supply could either validate or puncture private-market expectations. Over 6–18 months, wider retail access may broaden speculative demand, but fragmented venues and weak reference pricing could also increase volatility and dislocations rather than improve price discovery.

Contrarian point: the access narrative may be real, but it does not establish attractive expected returns. Avoid treating the perp’s implied market cap as a valuation supported by public-company fundamentals. No broad trade follows without current contract pricing, depth, funding and reliable reference data.

Key Decisions for Investors

• Do not chase pre-IPO perps solely on the democratization narrative. For Anthropic, wait for public filings and IPO terms before assessing valuation; verify audited revenue, growth, cash burn and dilution.
• Watch for a post-IPO convergence setup: compare any relevant perp’s implied valuation with the IPO valuation and actual share price, then consider a small, defined-risk fade only if the premium is persistent and order-book depth, funding and reference methodology are independently verified. Avoid an unhedged short where squeezes or forced liquidations could dominate.
• Treat SPCX as an event-volatility watch, not a directional recommendation based on the historical premium described. Reassess only against current trading, liquidity and company disclosures; the article provides no basis for an entry price or present-day mispricing.
• Falsifiers for a bearish-premium thesis: public filings and IPO pricing support the elevated valuation, the post-listing share price sustains or exceeds the perp-implied level, or persistent demand absorbs new share supply. Conversely, weak disclosures, a lower-than-implied IPO price, or widening perp funding/basis would strengthen the case to avoid or fade the contract.